Search Result

Results for "

dopaminergic receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adenosine Receptor (1) Adrenergic Receptor (4) Antibiotic (1) Apoptosis (16) Bacterial (1) Calcium Channel (4) Chloride Channel (1) Dopamine Receptor (15) Drug Metabolite (2) Endogenous Metabolite (25) Epigenetic Reader Domain (1) Ferroptosis (16) GABA Receptor (2) Glucocorticoid Receptor (1) Histamine Receptor (1) Histone Methyltransferase (1) iGluR (17) Isotope-Labeled Compounds (8) nAChR (5) Phosphodiesterase (PDE) (1) Serotonin Transporter (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Infection (1) Metabolic Disease (3) Neurological Disease (49)

By Targets:

5-HT Receptor (5)

Adenosine Receptor (1)

Adrenergic Receptor (4)

Antibiotic (1)

Apoptosis (16)

Bacterial (1)

Calcium Channel (4)

Chloride Channel (1)

Dopamine Receptor (15)

Drug Metabolite (2)

Endogenous Metabolite (25)

Epigenetic Reader Domain (1)

Ferroptosis (16)

GABA Receptor (2)

Glucocorticoid Receptor (1)

Histamine Receptor (1)

Histone Methyltransferase (1)

iGluR (17)

Isotope-Labeled Compounds (8)

nAChR (5)

Phosphodiesterase (PDE) (1)

Serotonin Transporter (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (3)

Infection (1)

Metabolic Disease (3)

Neurological Disease (49)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110080

Lisuride maleate	Dopamine Receptor	Neurological Disease
Lisuride (maleate) is a potent agonist of dopamine with a probably direct action on dopaminergic receptors. Lisuride (maleate) is an ergot derivative. Lisuride (maleate) releases the premenstrual mastalgia without significant side effects .

HY-W016498

Paraxanthine 2 Publications Verification	Drug Metabolite Endogenous Metabolite	Neurological Disease
Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-B1225

Promazine hydrochloride 1 Publications Verification Romtiazin hydrochloride; Ampazine hydrochloride; Berophen hydrochloride	Dopamine Receptor	Neurological Disease
Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D₂ antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .

HY-128975

m-Tyramine hydrobromide	Endogenous Metabolite	Neurological Disease
m-Tyramine hydrobromide is an endogenous trace amine neuromodulator. m-Tyramine hydrobromide has effects on the adrenergic and *dopaminergic* receptor ^{[1, 2]}.

HY-W016498S

Paraxanthine-d6	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
Paraxanthine-d₆ is the deuterium labeled Paraxanthine. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-160997

Prosulpride GRI 1665	Dopamine Receptor	Neurological Disease
Prosulpride (GRI 1665), a neuroleptics, can block selectively **dopaminergic receptor** .

HY-B1225A

Promazine Romtiazin; Ampazine; Berophen	Dopamine Receptor	Neurological Disease
Promazine (Romtiazin) is an antipsychotic and a dopamine receptor D₂ antagonist. Promazine inhibits dopaminergic neurotransmission .

HY-113356

m-Tyramine	Endogenous Metabolite	Neurological Disease
m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and *dopaminergic* receptor ^{[1, 2]}.

HY-19489S1

(Rac)-Levomepromazine-d3 hydrochloride (Rac)-Methotrimeprazine-d₃ hydrochloride	Isotope-Labeled Compounds Dopamine Receptor Histamine Receptor	Neurological Disease
(Rac)-Levomepromazine-d₃ (hydrochloride) is a labelled racemic Methotrimeprazine, which is a phenothiazine which has antagonist actions at multiple neurotransmitter receptor sites, including dopaminergic, cholinergic, serotonin and histamine receptors[1][2].

HY-120016

RU 43044	Glucocorticoid Receptor	Neurological Disease
RU 43044 is a glucocorticoid receptor antagonist. RU 43044 shows an antidepressant-like effect, probably via an inhibition of enhanced prefrontal dopaminergic neurotransmission in these mouse models .

HY-125602

MNI-444	Adenosine Receptor	Neurological Disease
MNI-444 is a BBB-penetrable ligand of adenosine 2A receptor (A2AR). A2AR is a potential non-dopaminergic target for the research of Parkinson’s disease .

HY-W016498R

Paraxanthine (Standard)	Drug Metabolite Endogenous Metabolite	Neurological Disease
Paraxanthine (Standard) is the analytical standard of Paraxanthine. This product is intended for research and analytical applications. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-B1225R

Promazine (hydrochloride) (Standard)	Dopamine Receptor	Neurological Disease
Promazine (hydrochloride) (Standard) is the analytical standard of Promazine (hydrochloride). This product is intended for research and analytical applications. Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D2 antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .

HY-B1864BR

Kasugamycin (hydrochloride hydrate) (Standard)	Bacterial Antibiotic	Infection
Promazine (hydrochloride) (Standard) is the analytical standard of Promazine (hydrochloride). This product is intended for research and analytical applications. Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D2 antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .

HY-B0799

Dihydroergotoxine mesylate Ergoloid mesylates	GABA Receptor Chloride Channel Adrenergic Receptor Dopamine Receptor Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease
Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABA_A receptor associated Cl ^- channel. Dihydroergotoxine mesylate also interacts with central **dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity .Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic** blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABA_A receptor associated Cl ^- channel. Dihydroergotoxine mesylate also interacts with central **dopaminergic and serotonergic receptors**. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity .

HY-155206

(+)-OSU6162	5-HT Receptor	Neurological Disease
(+)-OSU6162 is an stabilizer on *dopaminergic* and serotonergic brain signaling. (+)-OSU6162 is a partial agonist of 5-HT2A receptor. (+)-OSU6162 can be used for neurological research .

HY-B1225S

Promazine-d6 hydrochloride Romtiazin-d₆ hydrochloride; Ampazine-d₆ hydrochloride	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Promazine-d₆ (hydrochloride) (Romtiazin-d₆ (hydrochloride)) is deuterium labeled Promazine (hydrochloride). Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D₂ antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .

HY-B0282

Acetylcholine chloride Maximum Cited Publications 14 Publications Verification ACh chloride	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-W016498S1

Paraxanthine-13C4,15N3	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
Paraxanthine- ¹³C₄, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Paraxanthine. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-108976

Raclopride tartrate	Dopamine Receptor	Neurological Disease
Raclopride tartrate is a selective dopamine D₂/D₃ receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D₂ and D₃ receptors with K_is of 1.8 nM and 3.5 nM, respectively .

HY-103414

Raclopride 5+ Cited Publications	Dopamine Receptor	Neurological Disease
Raclopride is a dopamine D₂/D₃ receptor antagonist with potential antipsychotic effects. Raclopride binds to D₂ and D₃ receptors with K_is of 1.8 nM and 3.5 nM, respectively .

HY-14608

L-Glutamic acid 5+ Cited Publications	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-14608S7

L-Glutamic acid-d5	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S

L-Glutamic acid-13C	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S5

L-Glutamic acid-13C5	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[1].

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates **dopamine (DA) receptors** and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-14608A

L-Glutamic acid monosodium salt 5+ Cited Publications	iGluR Apoptosis Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-14608S1

L-Glutamic acid-1-13C	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-B0282S1

Acetylcholine-d9 chloride ACh-d₉(chloride)	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282S

Acetylcholine-d4 chloride ACh-d₄ (chloride)	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-14608S6

L-Glutamic acid-5-13C	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-106973A

Nolomirole hydrochloride CHF 1035	Dopamine Receptor Adrenergic Receptor	Cardiovascular Disease
Nolomirole (CHF 1035) hydrochloride is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output .

HY-B0282R

Acetylcholine chloride (Standard)	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine (chloride) (Standard) is the analytical standard of Acetylcholine (chloride). This product is intended for research and analytical applications. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-14608S3

L-Glutamic acid-13C5,15N	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2	Apoptosis iGluR Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].

HY-14608S9

L-Glutamic acid-15N,d5	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-19225A

Ensaculin free base KA-672; Anseculin	iGluR 5-HT Receptor Adrenergic Receptor Dopamine Receptor	Neurological Disease
Ensaculin free base (KA-672) is a NMDA antagonist and have high affinities to serotonergic 5-HT_1A and 5-HT₇ receptors, adrenergic α₁, and dopaminergic D₂ and D₃ receptors. Ensaculin free base is a memory-enhancing agent. Ensaculin free base has the potential as an antidementia agent acting on various transmitter systems .

HY-14608S4

L-Glutamic acid-13C5,15N,d5	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W424918

Opromazine hydrochloride	Dopamine Receptor	Neurological Disease
Opromazine hydrochloride is an antipsychotic medication that exhibits sedative and antiemetic pharmacological effects, making it effective for treating psychiatric disorders such as schizophrenia and psychosis. Opromazine hydrochloride functions by reducing dopaminergic activity through the blockade of dopamine receptors in the brain. Opromazine hydrochloride has been analyzed for its metabolites in various microsomal enzymes, revealing differences in formation rates that underscore the variability of drug-metabolizing enzymes in human liver and placenta microsomes.

HY-14608S12

L-Glutamic acid-14C L-Glutamic acid-¹⁴C	iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-14C is L-Glutamic acid (HY-14608) labeled with the radioactive isotope carbon-14. L-Glutamic acid is an excitatory amino acid neurotransmitter and an agonist for all subtypes of glutamate receptors (metabotropic, NMDA, and AMPA). L-Glutamic acid acts as an agonist in the release of DA from dopaminergic nerve terminals and can be used in the study of neurological diseases .

HY-100991

FG 7142 ZK 39106; LSU-65	GABA Receptor	Neurological Disease
FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the α1 subunit-containing GABAA receptor (K_i=91 nM). FG 7142 (ZK 39106; LSU-65) also modulates GABA-induced chloride flux at GABAA receptors expressing the α1 subunit (EC₅₀= 137 nM). FG 7142 (ZK 39106; LSU-65) can increase tyrosine hydroxylation and cause upregulation of β-adrenoceptors in mouse cerebral cortex .

HY-136390

ML417	Dopamine Receptor	Neurological Disease
ML417 is a selective and brain penetrant *D3 dopamine* receptor (D3R) agonist, with an EC₅₀** of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons .

HY-121311

Metrenperone	Serotonin Transporter Adrenergic Receptor	Cardiovascular Disease
Metrenperone is an inhibitor for 5-HT2 receptor. Metrenperone exhibits α1 and α2 antagonist activity as well as anti-H1 and anti-dopaminergic efficacy. Metrenperone can lower the blood pressure, enhances bradycardia in peripheral ischemia, inhibits serotonin-induced platelet aggregation, and antagonizes serotonin-mediated vasoconstriction. Metrenperone promotes the repair of acutely damaged collagen tissue .

HY-14608AR

L-Glutamic acid (monosodium salt) (Standard)	iGluR Apoptosis Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

HY-13409

SB 242084 4 Publications Verification	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-13409A

SB 242084 dihydrochloride 4 Publications Verification	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 dihydrochloride is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-160959

AN317	nAChR	Neurological Disease
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with K_i of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP ⁺. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .

HY-13409B

SB 242084 monohydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 monohydrochloride is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

Cat. No.	Product Name	Target	Research Area

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates **dopamine (DA) receptors** and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W016498

Paraxanthine 2 Publications Verification	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Drug Metabolite Endogenous Metabolite
Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-128975

m-Tyramine hydrobromide	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
m-Tyramine hydrobromide is an endogenous trace amine neuromodulator. m-Tyramine hydrobromide has effects on the adrenergic and *dopaminergic* receptor ^{[1, 2]}.

HY-B0282

Acetylcholine chloride Maximum Cited Publications 14 Publications Verification ACh chloride	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	nAChR Calcium Channel Endogenous Metabolite
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-14608

L-Glutamic acid 5+ Cited Publications	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-14608A

L-Glutamic acid monosodium salt 5+ Cited Publications	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-14608R

L-Glutamic acid (Standard)	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

HY-113356

m-Tyramine	Monophenols Source classification Disease markers Phenols Endogenous metabolite Cardiovascular System Disorder	Endogenous Metabolite
m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and *dopaminergic* receptor ^{[1, 2]}.

HY-W016498R

Paraxanthine (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Drug Metabolite Endogenous Metabolite
Paraxanthine (Standard) is the analytical standard of Paraxanthine. This product is intended for research and analytical applications. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-B0282R

Acetylcholine chloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	nAChR Calcium Channel Endogenous Metabolite
Acetylcholine (chloride) (Standard) is the analytical standard of Acetylcholine (chloride). This product is intended for research and analytical applications. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-14608AR

L-Glutamic acid (monosodium salt) (Standard)	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

Cat. No.	Product Name	Chemical Structure

HY-W016498S

Paraxanthine-d6
Paraxanthine-d₆ is the deuterium labeled Paraxanthine. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-W016498S1

Paraxanthine-13C4,15N3
Paraxanthine- ¹³C₄, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Paraxanthine. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S5

L-Glutamic acid-13C5
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[1].

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-19489S1

(Rac)-Levomepromazine-d3 hydrochloride
(Rac)-Levomepromazine-d₃ (hydrochloride) is a labelled racemic Methotrimeprazine, which is a phenothiazine which has antagonist actions at multiple neurotransmitter receptor sites, including dopaminergic, cholinergic, serotonin and histamine receptors[1][2].

HY-B1225S

Promazine-d6 hydrochloride
Promazine-d₆ (hydrochloride) (Romtiazin-d₆ (hydrochloride)) is deuterium labeled Promazine (hydrochloride). Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D₂ antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-B0282S1

Acetylcholine-d9 chloride

Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282S

Acetylcholine-d4 chloride

Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

dopaminergic receptors

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products